{"eventGroups":[{"deathsNumAffected":2,"deathsNumAtRisk":3,"description":"Vorinostat Oral Capsules 400mg daily\n\nVorinostat Oral Capsule: Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":3,"seriousNumAffected":2,"seriousNumAtRisk":3,"title":"Vorinostat, Zolinza Oral Capsules"}],"frequencyThreshold":"5","seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (Unspecified)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3,"numEvents":2}],"term":"Death of uterine carcinoma"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3,"numEvents":2}],"term":"pleural effusion"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (Unspecified)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"abscess of the vaginal vault"}],"timeFrame":"From enrolment to study completion per Patient, up to 41 weeks."}